Εμφάνιση απλής εγγραφής

dc.creatorSebastianelli A., Spatafora P., Morselli S., Vignozzi L., Serni S., McVary K.T., Kaplan S., Gravas S., Chapple C., Gacci M.en
dc.date.accessioned2023-01-31T09:54:54Z
dc.date.available2023-01-31T09:54:54Z
dc.date.issued2020
dc.identifier10.1007/s11934-020-01009-7
dc.identifier.issn15272737
dc.identifier.urihttp://hdl.handle.net/11615/78876
dc.description.abstractPurpose of Review: Aim of our systematic review is to evaluate and summarize the efficacy and safety of tadalafil alone or in combination with tamsulosin for the management of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). Recent Findings: Daily tadalafil, in particular 5 mg, according to retrieved studies, appears to be both safe and effective in treating LUTS/BPH and ED, compared with placebo or tamsulosin. The combination of daily tadalafil 5 mg and tamsulosin 0.4 mg allows a better improvement of LUTS compared with both the monotherapies, even if with an increased, but acceptable and tolerated, adverse events rate. After discontinuation of tamsulosin or tadalafil in patients previously treated with their combination, the improvement of LUTS retains significance compared with baseline. Summary: Tadalafil 5 mg should be considered a primary treatment option for patients with LUTS/BPH and ED. Evidence highlight an excellent tolerability, safety, and effectiveness profile, both alone or in combination with tamsulosin 0.4 mg. A better efficacy on LUTS relief has been observed for combination therapy, preserving also sexual function. The further switch to monotherapy allows to preserve LUTS relief, but tadalafil only is able to retain ED improvement. Our results support the evidence for a more and more tailored and modular LUTS treatment. © 2020, The Author(s).en
dc.language.isoenen
dc.sourceCurrent Urology Reportsen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85094197256&doi=10.1007%2fs11934-020-01009-7&partnerID=40&md5=c21d4f378ad650b579ae4193fb55ba94
dc.subjectplaceboen
dc.subjecttadalafilen
dc.subjecttamsulosinen
dc.subjecttadalafilen
dc.subjecttamsulosinen
dc.subjecturinary tract agenten
dc.subjectbackacheen
dc.subjectbladder outlet obstruction indexen
dc.subjectClinical Global Impression scaleen
dc.subjectcombination drug therapyen
dc.subjectdizzinessen
dc.subjectdrug dose comparisonen
dc.subjectdrug dose escalationen
dc.subjectdrug efficacyen
dc.subjectdrug safetyen
dc.subjectdrug tolerabilityen
dc.subjectdrug withdrawalen
dc.subjectdyspepsiaen
dc.subjecterectile dysfunctionen
dc.subjectheadacheen
dc.subjectheartburnen
dc.subjecthumanen
dc.subjecthyperemiaen
dc.subjecthypotensionen
dc.subjectInternational Index of Erectile Functionen
dc.subjectInternational Prostate Symptom Scoreen
dc.subjectlower urinary tract symptomen
dc.subjectmonotherapyen
dc.subjectmyalgiaen
dc.subjectnose obstructionen
dc.subjectocular hyperemiaen
dc.subjectpostvoid residual urine volumeen
dc.subjectprostate hypertrophyen
dc.subjectquality of lifeen
dc.subjectReviewen
dc.subjectrhinopharyngitisen
dc.subjectsexual satisfactionen
dc.subjectside effecten
dc.subjectsystematic reviewen
dc.subjecturine flow rateen
dc.subjectcomplicationen
dc.subjecterectile dysfunctionen
dc.subjectlower urinary tract symptomen
dc.subjectmaleen
dc.subjectmultimodality cancer therapyen
dc.subjectrandomized controlled trial (topic)en
dc.subjecttreatment outcomeen
dc.subjectCombined Modality Therapyen
dc.subjectErectile Dysfunctionen
dc.subjectHumansen
dc.subjectLower Urinary Tract Symptomsen
dc.subjectMaleen
dc.subjectProstatic Hyperplasiaen
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectTadalafilen
dc.subjectTamsulosinen
dc.subjectTreatment Outcomeen
dc.subjectUrological Agentsen
dc.subjectSpringeren
dc.titleTadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and EDen
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής